Accessibility Menu
Vaxcyte Stock Quote

Vaxcyte (NASDAQ: PCVX)

$42.26
(1.6%)
+0.66
Price as of October 24, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$42.26
Daily Change
(1.6%) +$0.66
Day's Range
$41.54 - $42.57
Previous Close
$42.26
Open
$42.22
Beta
0.82
Volume
28,994
Average Volume
1,697,461
Market Cap
5.5B
Market Cap / Employee
$42.23M
52wk Range
$27.66 - $116.00
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$4.19
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Vaxcyte Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
PCVX-62.4%-3.03%-0.61%+61%
S&P+16.9%+95.99%+14.39%+123%

Vaxcyte Company Info

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, and Jeff Fairman on November 27, 2013 and is headquartered in San Carlos, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit-$4.99M-43.4%
Market Cap$4.19B-48.9%
Market Cap / Employee$10.13M0.0%
Employees41463.0%
Net Income-$166.57M-29.4%
EBITDA-$221.23M-48.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$306.74M-40.9%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$79.54M334.9%
Short Term Debt$6.30M-13.6%

Ratios

Q2 2025YOY Change
Return On Assets-20.31%7.4%
Return On Invested Capital-25.69%15.9%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$130.92M21.5%
Operating Free Cash Flow-$121.17M0.2%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book6.362.981.431.31-68.35%
Price to Tangible Book Value6.362.981.431.31-68.35%
Enterprise Value to EBITDA-88.48-54.31-20.12-12.87-74.10%
Return on Equity-21.1%-20.4%-19.7%-21.7%-25.55%
Total Debt$27.96M$71.11M$87.21M$85.85M235.58%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.